Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
92 Leser
Artikel bewerten:
(0)

Biologic and Medical Imaging Reagents 2017: Applications & Industry Structure

DUBLIN, October 13, 2017 /PRNewswire/ --

The "Biologic and Medical Imaging Reagents: Global Markets" report has been added to Research and Markets' offering.

Research and Markets Logo

The scope of the study includes the biological imaging reagents that are already commercialized or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in vivo and in vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecast growth from 2017 through 2022. Technology status and market driving forces are also discussed.

Imaging reagent producers and the industry structure are examined in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biological imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biological imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.

Topics Covered in this Report Include:

  • Fluorescent dyes and probes.
  • Fluorescent proteins.
  • Nanoparticles, including quantum dots.
  • Supermolecules.
  • Imaging radiopharmaceuticals.
  • Contrast reagents for X-ray/CT, MRI and ultrasound.

Topics not Covered in this Report Include:

  • Nanotechnology.
  • Drug delivery.
  • Coatings.
  • Supramolecular chemistry.
  • Imaging instruments and software.

Companies Mentioned

  • ABT Molecular Imaging Inc.
  • ABX Advanced Biochemical Compounds Gmbh
  • Active Motif Chromeon Gmbh
  • Acusphere Inc.
  • Advanced Accelerator Applications Sa
  • Advanced Proteome Therapeutics Inc.
  • Advanced Research Technologies Inc.
  • Affibody Ab
  • Agenix Ltd.
  • Alseres Pharmaceuticals Inc.
  • Alzhyme Pty Ltd.
  • Amag Pharmaceuticals Inc.
  • American Dye Source Inc.
  • American Elements
  • Anaspec Inc.
  • Anticancer Inc.
  • Aposense
  • Areva
  • Astellas Pharma Inc.
  • Astrazeneca Ltd.
  • (100+ Others)

Key Topics Covered:

1: Introduction

2: Executive Summary

3: Overview

4: Biological Imaging Technologies

5: Biological Imaging Reagents Applications

6: Biological Imaging Reagents Industry Structure

7: Competitive Landscape

8: Biological Imaging Reagents Markets

9: Patent Status

10: Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/dfkrq3/biologic_and

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.